• 1
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354: 19329.
  • 2
    Padyukov L, Lampa J, Heimburger M, Ernstam S, Cederholm T, Lundkvist I, et al. Genetic markets for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 5269.
  • 3
    Binsadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111: 697703.
  • 4
    De Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, et al. A triallelic Fcγ receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcγRIIIa. J Immunol 1996; 156: 394855.
  • 5
    Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002; 14: 798802.
  • 6
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG receptor FcγRIIIa gene. Blood 2002; 99: 7548.
  • 7
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 4559.
  • 8
    Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, et al. A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping. J Immunol Methods 2000; 242: 12732.
  • 9
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmembrane TNF and activates immune effector functions. Cytokine 1995; 7: 2519.
  • 10
    Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 154861.
  • 11
    Van Deventer SJ. Transmembrane TNFα, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 12425.
  • 12
    Ulfgren AK, Catrina A, af Klint E, Trollmo T, Klareskog L. Evidences that anti tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages but not lymphocytes in RA joints [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S373.
  • 13
    Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004; 116: 4917.
  • 14
    Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003; 23: 7685.
  • 15
    Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class 1-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004; 113: 132833.
  • 16
    Capone L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, Pratesi F, et al. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis 2005; 64: 58793.